Anti-Hypertensive Drugs - Austria

Austria

The Anti-Hypertensive Drugs market in Austria is predicted to witness a significant growth in revenue, reaching US$71.31m in 2024.
This projection is based on the expected annual growth rate (CAGR 2024-2029) of 0.07%, which indicates that the market volume is projected to reach US$71.57m by 2029.
When compared to other countries globally, United States is expected to generate the highest revenue in the Anti-Hypertensive Drugs market, with an estimated revenue of US$12,290.00m in 2024.
Austria's demand for anti-hypertensive drugs has been steadily increasing due to the country's aging population and rising prevalence of hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Austria has been experiencing significant growth in recent years.

Customer preferences: The rising prevalence of hypertension in the country has led to an increased demand for anti-hypertensive drugs. Additionally, the aging population in Austria has also contributed to the growth of this market.

Trends in the market: One trend in the Anti-Hypertensive Drugs market in Austria is the shift towards combination therapies. Patients are increasingly being prescribed multiple drugs to manage their hypertension, and pharmaceutical companies are responding by developing combination drugs that are more convenient for patients to take.Another trend is the increasing use of generic drugs. With the rising cost of healthcare in Austria, patients and healthcare providers are looking for ways to reduce costs. Generic drugs are often cheaper than their brand-name counterparts, and as a result, they are becoming more popular in the Anti-Hypertensive Drugs market.

Local special circumstances: Austria has a strong healthcare system that provides universal coverage to its citizens. This has helped to increase access to anti-hypertensive drugs for patients who need them. Additionally, the country has a well-developed pharmaceutical industry, which has contributed to the growth of the Anti-Hypertensive Drugs market.

Underlying macroeconomic factors: The Austrian economy has been growing steadily in recent years, which has helped to increase demand for healthcare services, including anti-hypertensive drugs. Additionally, the country's aging population is expected to continue to drive growth in this market in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.